1
Allogeneic γδ T Cell Therapy for Treatment of Patients With Advanced Solid Cancers
Condition(s):Advanced Solid TumourLast Updated:February 24, 2021Recruiting
Allogeneic γδ T Cells, AREA[OverallStatus], Open or Pending: 8 Clinical Trials
Include Studies Not Open or Pending
2
Allogeneic γδ T Cells Immunotherapy in r/r Non-Hodgkin’s Lymphoma (NHL) or Peripheral T Cell Lymphomas (PTCL) Patients
Condition(s):Non-Hodgkin’s Lymphoma (NHL); Peripheral T Cell Lymphoma (PTCL)Last Updated:January 6, 2021Recruiting
3
Haplo / Allogeneic NKG2DL-targeting Chimeric Antigen Receptor-grafted γδ T Cells for Relapsed or Refractory Solid Tumour
Condition(s):Colorectal Cancer; Triple Negative Breast Cancer; Sarcoma; Nasopharyngeal Carcinoma; Prostate Cancer; Gastric CancerLast Updated:September 27, 2019Not yet recruiting
4
TCB008 in Patients With COVID-19
Condition(s):Covid19Last Updated:April 6, 2021Not yet recruiting
5
Allogeneic “Gammadelta T Cells (γδ T Cells)” Cell Immunotherapy in Phase 1 Hepatocellular Carcinoma Clinical Trial
Condition(s):Hepatocellular CarcinomaLast Updated:August 19, 2020Recruiting
6
Preemptive Infusion of Donor Lymphocytes Depleted of TCR + T Cells + CD19+ B Cells Following ASCT
Condition(s):Allogeneic Stem Cell Transplant Candidate; Acute Myeloid/Lymphoblastic Leukemia; Myelodysplastic Syndrome; Myeloproliferative Neoplasm; Lymphoproliferative DisordersLast Updated:April 19, 2021Not yet recruiting
7
A Study of ADI-001 in B Cell Malignancies
Condition(s):Lymphoma, Follicular; Lymphoma, Mantle-Cell; Marginal Zone Lymphoma; Lymphoma, Burkitt; Mediastinal Lymphoma; Diffuse Large B Cell Lymphoma; Lymphoma, Non-Hodgkin; Lymphoma, Large B-Cell, DiffuseLast Updated:March 8, 2021Recruiting
8
Alpha/Beta T-cell Depleted Blood-forming Stem Cell Transplant From Related or Unrelated Donors for Blood Diseases in Children and Young Adults
Condition(s):Blood DiseaseLast Updated:April 15, 2021Not yet recruiting